Entera Bio Ltd. (ENTX)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
ENTX price, last 12 months
Key stats
- Previous close
- $2.80
- Open
- $2.91
- Day range
- $2.70 – $2.91
- 52-week range
- $0.9100 – $4.20
- Volume
- 776.3K
- Avg volume (20 days)
- 411.5K
- Market cap
- $475.3M
Performance
Technicals and fundamentals
About Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $475.3M